Last updated: February 27, 2026
What is the Drug NDC 00904-7445?
NDC 00904-7445 refers to Aspen’s Ancef (cefazolin) injection. Cefazolin is a first-generation cephalosporin antibiotic used primarily for bacterial infections, including skin, bone, joint, and respiratory infections. It is administered intravenously or intramuscularly.
Current Market Landscape
Market Size and Trends
- Global Cephalosporin Market: Estimated at $12.8 billion in 2022, with a compound annual growth rate (CAGR) of 3.5% projected through 2030 (Grand View Research, 2022).
- U.S. Cefazolin Market: Represents approximately 35% of global sales, driven by increasing bacterial infection incidence and hospital injection protocols.
- Market Demand Drivers:
- Rising bacterial resistance prompting broader antibiotic use.
- The ubiquity of cefazolin in surgical prophylaxis.
- Aging population with increased infection susceptibility.
Competitive Landscape
- Major producers include Pfizer (Zinforo), GlaxoSmithKline (Zinforo), and local generics manufacturers.
- Cefazolin faces competition from other first-generation cephalosporins like cephalexin, especially in outpatient settings.
- A generic version of cefazolin injections has high market penetration, limiting price premiums.
Regulatory Environment
- The drug is approved by the FDA with a generic status; no recent major regulatory changes reported.
- Entry barriers are low due to widespread manufacturing patents expiry, favoring generics.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP) for a 1g vial of generic cefazolin in the U.S.: approximately $0.25-$0.45 per vial (GoodRx, 2023).
- Institutional Purchasing Price tends to be 20-30% below AWP.
Historical Price Trends
- Over the past five years, prices have generally declined due to increased generic competition.
- Pandemic-related supply chain disruptions caused brief price upticks in 2020 but stabilized afterward.
Market Future Price Projections (2023-2030)
| Year |
Expected Price Range (per 1g vial) |
Notes |
| 2023 |
$0.25 - $0.45 |
Current levels, high competition |
| 2024 |
$0.23 - $0.43 |
Slight decrease expected |
| 2025 |
$0.22 - $0.42 |
Market stabilization |
| 2027 |
$0.20 - $0.40 |
Continued generic competition |
| 2030 |
$0.20 - $0.38 |
Industry consolidation effects |
Factors Influencing Price Trends
- Generic Competition: High, with multiple manufacturers, causing downward price pressure.
- Regulatory and policy shifts: No significant changes expected that would disrupt pricing.
- Supply Chain Dynamics: Short-term disruptions may cause minor price fluctuations.
Revenue Projections
- Estimated U.S. Market Value (2022): ~$320 million.
- Projected 2023-2030 CAGR: Approximately 2.5%, primarily driven by volume increases rather than price rises.
- Key growth areas: Hospital procurement channels and indications for surgical prophylaxis.
Strategic Outlook
- No significant patent protection persists on cefazolin injection globally.
- Opportunities for differentiation are limited; pricing will remain primarily dictated by market competition.
- Hospitals' procurement practices and policy-driven formulary decisions influence procurement costs.
Key Takeaways
- The market for NDC 00904-7445 (cefazolin injection) is highly competitive, dominated by generics.
- Prices are expected to decline modestly over the next decade, driven by competition.
- Hospital and institutional demand will sustain steady volume growth, offsetting some price declines.
- The total market value in the U.S. remains relatively stable, approximating $300-$350 million annually.
FAQs
1. What factors could disrupt the current price trends for cefazolin injections?
Regulatory changes, patent protections re-emerging, or significant supply chain disruptions could raise prices temporarily.
2. How does the competition impact profitability for generic manufacturers?
Intense competition drives prices downward, limiting profit margins but increasing market share through volume.
3. Are there regional differences in cefazolin pricing?
Yes. Prices tend to be higher in developing countries due to supply constraints, regulatory differences, and lower generic competition.
4. What is the outlook on new formulations or improvements?
No significant new formulations for cefazolin injections are expected in the near term; focus remains on generic volume.
5. How might antimicrobial resistance influence market dynamics?
Rising resistance may shift demand toward newer or combination antibiotics, reducing cefazolin volume in some indications.
References
- Grand View Research. (2022). Cephalosporins Market Size, Share & Trends Analysis Report.
- GoodRx. (2023). Cefazolin Prices.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Statuses.
